Abstract:Background Invasive fungal infection (IFI) is a common and fatal complication in neutropenic patients with hematological malignancy. Empirical antifungal therapy is widely used in practice due to the difficulty of pathogens determination and illness of the hosts. The aim of this study was to evaluate the efficacy and safety of itraconazole as empirical antifungal therapy for persistent fever in neutropenic patients with hematologic malignancies.Methods Two hundred and seventy-four patients with hematologic malignancies who had suspected fungal infections were enrolled in 18 centers across China between April 2008 and April 2009. Empirical antifungal therapy with intravenous itraconazole 200 mg twice daily was given for the first two days, followed by 200 mg once daily for the next 12 days. Oral itraconazole solution was sequential for follow-up therapy if necessary. Five composite end points were evaluated for the response, which was more restrictive and adopted for the first time in such study in China.Results The intent-to-treat analysis included data from 274 patients (full analysis set, FAS), of whom 248 were included as the per-protocol population (PPS). As the composite end point of five indices was concerned, the overall response rate was 43.4%. Seperately, defervescence was achieved in 90% of patients in which 55.5% occured during neutropenia. The mean time to defervescence was 2.71 days. Absence of breakthrough IFI during drug administration or within the first 7 days after study completion was observed in 71.5% of patients. Fifty-five point five percent patients with IFI at baseline was successfully treated. Ninety point five percent patients survived for at least 7 days after completing the study. PPS analysis revealed that the duration of neutropenia >= 10 days was a statistically significant negative predictor for the response. The withdrawal rate due to drug-related toxicity or lack of efficacy was 11.0%. The incidence of adverse events was 22.6%, in which 11.6% was study drug related. The most frequent adverse events were mild to moderate liver toxicity.Conclusion ltraconazole shows desirable efficacy and safety as empirical antifungal therapy for febrile neutropenic patients with hematologic malignancies. Chin Med J 2011;124(22):3670-3675

Clinical Study of Efficacy and Levels of Itraconazole in Serum and Nail Samples of Toenail Onychomycosis Treatment with Itraconazole Intermittent Pulse Therapy

Levels of Itraconazole in Serum and Nail Samples of Toenail Onychomycosis by Intermittent Pulse Therpy

Terbinafine versus itraconazole for treatment of dermatophyte onychomycosis: a meta-analysis

Treatment of onychomycosis by pulse usage of itraconazole

Efficacy and Safety of Itraconazole on Invasive Fungal Infections in 66 Patients with Malignant Hematological Diseases

Efficacy and Safety of Itraconazole As Empirical Antifungal Therapy in Febrile Neutropenic Patients with Hematologic Malignancies: an Open-Lable, Multicenter, Observational Trial in A Chinese Cohort

A Clinical Trial of Intravenous Itraconazole Followed by Itraconazole Capsule in the Treatment of 25 Cases of Systemic Fungal Infection

Randomized, double-blind, comparative study on efficacy and safety of itraconazole pulse therapy and terbinafine pulse therapy on nondermatophyte mold onychomycosis: A study with 90 patients

Meta-analysis on Efficacy and Safety of Terbinafine and Itraconazole in Treatment of Onychomycosis

Clinical study on the efficacy and safety of intravenous itraconazole infusion for the treatment of invasive fungal infection in China

Determination of Itraconazole in Human Nail Samples Using High Performance Liquid Chromatography with Fluorescence Detection

Efficacy of topical trichloroacetic acid 100% either alone or combined with topical tioconazole 28% versus systemic itraconazole in the treatment of onychomycosis

Preparation of Topical Itraconazole with Enhanced Skin/Nail Permeability and In Vivo Antifungal Efficacy against Superficial Mycosis

[Efficacy of Intravenous Administration of Itraconazole on Fungal Infections in Immunocompromised Patients with Hematological Diseases].

Trough Concentration of Itraconazole and Its Relationship with Efficacy and Safety: a Systematic Review and Meta-Analysis

Efficacy of terbinafine and itraconazole in different doses and in combination in the treatment of tinea infection: A randomized controlled parallel group open labeled trial with clinico-mycological correlation

Meta-analysis of Therapeutic Efficacy of Itraconazole Against Invasive Fungal Infection in Hematology Patients

A Randomized Control Study of Oral Itraconazole versus Itraconazole with Terbinafine in the Treatment of Dermatophytosis

Extended Use of Topical Efinaconazole Remains Safe and Can Provide Continuing Benefits for Dermatophyte Toenail Onychomycosis

Itraconazole Oral Solution in Treatment of Oral Candidiasis in 40 Patients

A Retrospective Study of Efficacy and Safety of Itraconazole for Treatment of Invasive Fungal Infection in Hematologic Diseases